

Appointments

Marco Pintore, Chief Executive Officer, and Judit Nagy, Chief Financial Officer, of GenoTher, a biocluster of excellence in the field gene therapies

Marco Pintore and Judit Nagy join the management committee of GenoTher, the biocluster dedicated to accelerating the development of gene therapies, from research to industrial production, certified under the France 2030 Plan, as Chief Executive Officer and Chief Financial Officer, respectively.



Marco Pintore, Chief Executive Officer

With a PhD in biochemistry, Marco Pintore has worked successively at the interface between the world of academic research, the private and entrepreneurial sector, and the institutional environment, with a focus on innovation in healthcare. Initially deputy director of a laboratory at the University of Orleans, he co-founded and ran R&D and innovation financing consulting services companies for 15 years. After heading the BioValley France health competitiveness cluster between 2017 and 2022, Marco Pintore spent the last three years as Senior VP of a large group in the contract research sector. **As CEO of GenoTher, Marco Pintore will coordinate the various components of the biocluster, including the establishment of scientific and**

technological platforms and the close monitoring of their operations and economic activities, the implementation and monitoring of training, entrepreneurship, and business creation initiatives, and public-private industrialization and innovation projects between GenoTher members.

Judit Nagy, Administrative and Financial Director.

With a demanding academic background in political science, finance, and history, and more than 20 years of international and multi-sector experience in financial management in France and abroad, **Judit Nagy takes over as Administrative and Financial Director of GenoTher. She will be responsible for structuring the biocluster's operations and promoting effective collaboration between the various partners and stakeholders involved.**



About GenoTher

Born out of the vision of its founders—Généthon, AP-HP, Genopole, Inserm, Université d'Évry Paris-Saclay, Spark Therapeutics, and Yposkesi—GenoTher is a large-scale project rooted in a region that is a pioneer in gene therapies. Its ambition is to create an ecosystem of excellence in France dedicated to gene therapies by bringing together key players in the sector in order to accelerate the development of gene therapy treatments from research to industrialization, respond to the growing challenges of bioproduction, promote the creation and financing of start-ups specializing in the field, and develop training for students and professionals in the sector's key skills. **LinkedIn:** [GenoTher](https://www.genother.org)

www.genother.org